Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma.

Biomedicines · 2022 · PMC9496184 · PMID 36140430

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a strong trendp = 0.05actually significant

Patients in the ecleralimab group showed a strong trend towards a significant ( p = 0.05) increase in the minimum absolute FEV 1 during LAR vs.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.